DrugPatentWatch Database Preview

Details for Patent: 9,034,867

« Back to Dashboard

Which drugs does patent 9,034,867 protect, and when does it expire?

Patent 9,034,867 protects ARISTADA and is included in one NDA.

This patent has thirty-five patent family members in twenty-two countries.

Summary for Patent: 9,034,867

Title:	Pharmaceutical compositions comprising sorbitan esters
Abstract:	The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
Inventor(s):	Perry; Jason M. (Cambridge, MA), Deaver; Daniel R. (Franklin, MA), Hickey; Magall B. (Medford, MA), Remenar; Julius F. (Waltham, MA), Vandiver; Jennifer (Arlington, MA)
Assignee:	ALKERMES PHARMA IRELAND LIMITED (Dublin, IE)
Application Number:	13/423,606
Patent Claim Types: see list of patent claims	Composition; Compound; Delivery; Use;

Drugs Protected by US Patent 9,034,867

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-001	Oct 5, 2015		RX	Yes	No			Y			TREATMENT OF SCHIZOPHRENIA
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No			Y			TREATMENT OF SCHIZOPHRENIA
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes			Y			TREATMENT OF SCHIZOPHRENIA

International Family Members for US Patent 9,034,867

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012231160
Australia	2017204486
Australia	2019202633